Challenges to medications development in treating alcohol dependence: an international perspective.
Few medications for treating alcohol dependence exist. Greater partnership is needed between academia and the pharmaceutical industry to develop, licence and market efficacious medications for treating alcohol dependence. Methodologies that span the divide between preclinical and large-scale clinical studies need to be developed in order to provide sufficient information on safety, toleration, drug-interaction profile and efficacy, with which to guide development decisions. Due to the heterogeneous nature of alcohol dependence, the effort of developing an efficacious medication is likely to be enhanced by clearer choices about the characteristics of the population. Careful consideration of potential mechanism of action of the putative therapeutic medication should enable the appropriate choice of drinking endpoint. The pharmaceutical industry in collaboration with academia might need to develop new approaches to determining appropriate treatment endpoints with regulatory bodies. The investment risk to industry should be appraised not only in terms of the rather poor results of previous marketing efforts but with a view to the opportunity to penetrate a potentially enormous and largely untapped market.
Littleton
John M
JM
Department of Molecular and Biomedical Pharmacology, University of Kentucky, Cooper and University Drives, Lexington 40546-0236, USA. jlittlet@uky.edu
De Witte
Philippe
P
Litten
Raye
R
Gessa
Gian Luigi
GL
Spanagel
Rainer
R
Kranzler
Henry
H
Lehert
Philippe
P
Johnson
Bankole
B
Saunders
John
J
Berglund
Mats
M
Harris
Adron
A
Anton
Raymond
R
Mann
Karl
K
D000437:Alcoholism / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000379:methods; D004345:Drug Industry / Q000379:methods*; D006801:Humans; D038622:Internationality